Article Text

Download PDFPDF
Changes in quality of life in people with Parkinson’s disease left untreated at diagnosis
  1. P Asimakopoulos1,
  2. R Caslake2,
  3. C E Harris2,
  4. J C Gordon2,
  5. K S M Taylor3,
  6. C Counsell2
  1. 1
    Crosshouse Hospital, Kilmarnock, UK
  2. 2
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, UK
  3. 3
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
  1. Dr C Counsell, Department of Medicine and Therapeutics, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK; carl.counsell{at}


Background: The issue of whether to adopt a “wait and watch” strategy or to initiate drug therapy soon after diagnosis in Parkinson’s disease (PD) has been the subject of some debate. A recent observational study supported early treatment by demonstrating deterioration in self-reported health status in those left untreated, but not those who received therapy. We aimed to replicate this observation.

Methods: People with PD from a prospective incidence study underwent follow-up with yearly clinical assessment of parkinsonian impairment (Unified Parkinson’s Disease Rating Scale (UPDRS)) and self-reported health status (Parkinson’s Disease Questionnaire (PDQ-39)). Two year outcomes were compared with those who started treatment within 1 year of diagnosis and those left untreated.

Results: 42 patients with PD were followed-up for 2 years, of whom 26 started treatment during the first year and 16 remained untreated. Those receiving treatment had significantly higher UPDRS and PDQ-39 scores at baseline. There was no significant deterioration in PDQ-39 score in either group (median change untreated 0.8 vs treated 4.0; p = 0.47), despite a significant difference in the change in motor UPDRS scores (untreated 6.0 vs treated −6.0; p = 0.03).

Conclusion: Given the lack of significant deterioration in the PDQ-39 in untreated patients, we believe a “wait and watch” strategy for the treatment of newly diagnosed PD remains a credible approach unless randomised trials prove otherwise.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: RC is supported by a grant from the Parkinson’s Disease Society.

  • Competing interests: None.

Linked Articles